← Back to patent-cliff list
ATX-101 (APIM Therapeutics)
Tier C — Watch / tradeATX-101 (APIM Therapeutics)
Apim Therapeutics
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PCNA
Indications (approved)：Leiomyosarcoma, 脂肪肉瘤, Glioblastoma, Peritoneal cancer, Ovarian cancer, Fallopian tube cancer, 子宫内膜样癌
Regional status
US
-
EU
Phase II
2024-05-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of ATX-101 (APIM Therapeutics)?
Approved indications include: Leiomyosarcoma, 脂肪肉瘤, Glioblastoma, Peritoneal cancer, Ovarian cancer, Fallopian tube cancer, 子宫内膜样癌.
When does the ATX-101 (APIM Therapeutics) patent expire?
No public expiry year is available for ATX-101 (APIM Therapeutics) yet; this page updates once verified.
How do I get a quote for ATX-101 (APIM Therapeutics) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06